{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 30 of 92', 'CR845-CLIN3103', 'blind Treatment Period. Electrocardiograms (ECGs) will be monitored at the Screening', 'Visit and Day 85 or Early Termination Visit.', 'The number and reason(s) for missed dialysis as well as the use of antipruritic', 'medications will be recorded throughout the study.', 'A Structured Safety Evaluation will be performed weekly (preferably on', 'Wednesday/Thursday) during the Double-blind Treatment Period. The Structured Safety', 'Evaluation is performed by study staff using a list of specific signs/symptoms (eg, mental', 'status change, falls, gait disturbance).', '6.1.2', 'Open-label Extension Phase', 'Patients who received at least 30 doses of study drug (either placebo or active) during the', '12-week Double-blind Treatment Period and continue to meet other eligibility criteria', 'will be eligible to receive open-label CR845 for an additional 52 weeks. The Open-label', 'Extension Phase will be comprised of the Open-label Treatment Period and the Follow-', 'up Period. The first visit and first dosing for the Open-label Extension Phase of the study', 'will occur immediately on the day of the last visit of the Double-blind Treatment Period', 'or up to 1 week following the Double-blind Treatment Period. Each patient will receive', 'CR845 at a dose of 0.5 mcg/kg after each dialysis session, 3 times per week for up to 52', 'weeks, whether they had been previously administered placebo or CR845. Prescription', 'dry body weight will be recorded at the start of and every 12 weeks during the Open-label', 'Extension Phase; if there is a +10% or more change from the prescription dry body', 'weight recorded at Screening, then the CR845 dose will be adjusted according to the', 'newly recorded dry body weight.', 'Patients will complete the 5-D Itch Scale during Weeks 4, 8, 12, 24, 36, and 52', '(preferably at the end of the specified weeks).', 'Clinical laboratory tests, vital signs, adverse events, and concomitant medications will be', 'monitored throughout the Open-label Treatment Period. Blood samples for inflammatory', 'biomarkers will be collected periodically until the End-of-Treatment or Early', 'Termination Visit. An electrocardiogram will be performed at the End-of-Treatment or', 'Early Termination Visit.', 'The number and reason(s) for missed dialysis and the use of antipruritic medications will', 'be recorded throughout the Open-label Extension Phase.', 'The last dose of open-label study drug will be administered at the last dialysis visit in', 'Week 52.', '6.1.3', 'Follow-up Period', 'A final safety Follow-up Visit will be conducted 7-10 days after the End-of-Treatment', 'Visit of the Double-blind Treatment Period for patients not participating in the Open-', 'label Extension Phase, after the End-of-Treatment Visit of the Open-label Extension', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 31 of 92', 'CR845-CLIN3103', 'Phase, or after the Early Termination Visit during either the Double-blind Treatment', 'Period or the Open-label Extension Phase.', 'Vital signs, adverse events, and concomitant medications will be monitored during the', 'Follow-up Period.', 'The study schematic is shown in Figure 1.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}